Since the risk assessment published by ECDC in August 2021 on the risk of vCJD disease transmission via blood and PDMP manufactured from donations obtained in the UK, no new cases of vCJD associated with dietary exposure or transfusion of blood or blood components have been reported in EU/EEA or in the rest of the world.
ECDC assessed the risk to the EU/EEA of the presence and the possible transmission of prions, which have been linked to Creutzfeldt-Jakob disease, by blood and plasma-derived medicinal products (PDMPs) manufactured from donations obtained in the UK.
The European Centre for Disease Prevention and Control was asked by the European Commission to assess the risk involved in changing the testing requirements for HIV (human immunodeficiency virus), hepatitis B virus (HBV), and hepatitis C virus (HCV) with regard to the quality and safety of non-partner semen donations.
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.
Two developments in the field of variant Creutzfeldt–Jakob disease (vCJD) occurred in 2009. In order to address a number of questions that were raised, ECDC internal and external experts prepared this risk assessment. The document focuses on how these new facts affect the current assumptions regarding transmissibility of the disease through blood transfusion and tissue/cells transplantation.